StratCap President Jim Condon Joins Praxis Solutions Advisory Committee
Mr. Condon is President and Managing Partner of StratCap, where he leads the firm's strategic initiatives and oversees operations across real estate, infrastructure, and digital economy investment solutions. During his 14 years at StratCap, he has played a pivotal role in the firm's evolution and expansion into digital transformation themes. He also served as a Board Member of Pegasus Digital Mobility Corp, helping guide strategy in emerging technology sectors.
Earlier in his career, Mr. Condon held leadership roles at PC Capital, Schroders, Refco, and Marsh & McLennan. He earned his MBA cum laude from the University of Notre Dame's Mendoza College of Business and holds a CIMA designation from The Wharton School.
"We're excited to welcome Jim Condon to the Praxis Advisory Committee," said Bill Dwyer, Executive Chairman of Praxis Solutions. "Jim has deep experience across institutional capital raising, private equity, and digital infrastructure. His insights will be instrumental as we scale Anchor Advisory and continue refining our AI-powered platform, KAIA, for investment due diligence and distribution."
"I've spent my career at the intersection of capital formation and innovation," said Mr. Condon. "Praxis is building the tools the industry needs—faster, smarter ways to conduct diligence, scale engagement, and improve product selection. I'm thrilled to support their vision and help shape the firm's next stage of growth."
As a member of the Advisory Committee, Mr. Condon will provide guidance on market expansion, institutional partnerships, and product strategy. His experience will help advance the reach and capabilities of both KAIA and Anchor Advisory Services, Praxis' distribution support arm focused on helping asset managers grow with speed and precision.
About Praxis SolutionsPraxis Solutions, based in Newport, CA, is a technology-enabled solutions provider transforming wealth and asset management firms. By combining deep industry expertise with advanced technology, Praxis helps clients improve deliverables and reduce costs. Visit www.praxissolutions.com for more information.
Media ContactWill DwyerPraxis Solutions, Inc.978-273-5563
View original content to download multimedia:https://www.prnewswire.com/news-releases/stratcap-president-jim-condon-joins-praxis-solutions-advisory-committee-302484332.html
SOURCE Praxis Solutions, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 days ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ('Praxis' or the 'Company') (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study. On this news, Praxis's stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980
Business Wire
6 days ago
- Business Wire
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ('Praxis' or 'the Company') (NASDAQ: PRAX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Praxis announced its Q2 2025 financial results on August 4, 2025. The Company reported mid-state clinical results from the trial of vormatrigine, an anti-seizure medication. The Company admitted that more than half of patients experienced treatment-emergent adverse events, with almost 25% of study participants discontinuing the medication. Based on this news, shares of Praxis fell more than 5% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
08-08-2025
- Yahoo
CIMA, MIA extend MoU to enhance growth in Malaysia
The Chartered Institute of Management Accountants (CIMA) and the Malaysian Institute of Accountants (MIA) have extended their memorandum of understanding (MoU) for an additional three years. The latest MoU aims at advancing accounting and finance talent growth in Malaysia. Under the agreement, MIA members with at least six years of relevant professional experience can pursue CIMA membership through a fast-track route. This involves passing the CGMA Strategic Case Study exam and fulfilling the necessary practical experience criteria. CIMA Southeast Asia regional director Saritha Subramaniam said: 'We are proud to renew our Memorandum of Understanding with MIA, reaffirming our shared commitment to advancing the accounting and finance profession in Malaysia and beyond. 'Our long-standing collaboration underscores our mutual commitment to driving professional excellence, delivering impactful initiatives to develop future-ready talent, and fostering global connectivity.' The collaboration has historically supported career advancement for professionals in accounting, finance, and business, while providing Malaysian employers with access to a wider, globally competitive talent pool. MIA membership operations director Ho Foong Chin said: 'This collaboration with CIMA is a gateway to the CGMA designation, as it provides MIA members with a well-defined pathway to specialise in management accounting and business strategy, while reinforcing our commitment to their professional advancement and long-term growth.' Earlier in August 2025, CIMA and ICAEW endorsed the UK Government's small business plan, which aims to strengthen fundamentals by enacting laws to stop late payments, costing the UK economy £11bn annually, and also reducing regulatory costs by 25%. "CIMA, MIA extend MoU to enhance growth in Malaysia" was originally created and published by The Accountant, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
